Invests in categories: MedTechHealthTechDevelopmentProductDrugCareHardwareBioTechDiagnosticsIT
Gilde Healthcare is a specialized healthcareinvestor managing over €1.4 billion acrosstwo fund strategies: Venture&Growthand Private Equity.
News
503
Portfolio
66
Mentions
105
Employees: 11-50
Investment Stage: Series A; Series B; Series C; Series E
Portfolio 66
Show more
News 503
| Date | Title | Description |
| 05.10.2021 | Nyxoah announces CE-mark approval to treat Complete Concentric Collapse (CCC) patients | Utrecht, The Netherlands & Mont-Saint-Guibert, Belgium - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to tr... |
| 04.10.2021 | Noema Pharma appoints Jeffrey Jonas as independent Chairman of the Board of Directors | Utrecht, The Netherlands & Basel, Switzerland - Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of D... |
| 29.09.2021 | Acacia Pharma announces Marketing Authorization Application for BARHEMSYS® in Europe | Utrecht, The Netherlands, Cambridge, UK & Indianapolis, US - Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoin... |
| 24.09.2021 | Gilde Healthcare names Robert Stein as Partner in Germany | With more than 25 years of Private Equity investment experience in ‘Mittelstand’ companies in the DACH Region and Europe, Robert will join the Private Equity team of Gilde Healthcare and operate out of the local Frankfurt office to further ... |
| 21.09.2021 | Amphista Therapeutics appoints new chairman, Joshua T. Brumm | Utrecht, The Netherlands & Glasgow, Scotland - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeed... |
| 15.09.2021 | Nyxoah announces U.S. FDA breakthrough device designation granted for the Genio® system for obstructive sleep apnea and complete concentric collapse | Utrecht (the Netherlands) & Cambridge (Massachusetts - US) - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions t... |
| 08.09.2021 | AM-Pharma signs exclusive license agreement with Kyowa Kirin for commercialization of ilofotase alfa in Japan | Utrecht, The Netherlands & Tokyo, Japan - AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), a global specialty pharmaceutical company... |
| 05.08.2021 | Noema Pharma initiates Phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome | Basel – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in ... |
| 14.07.2021 | Spire Health closes $38 million financing round led by Gilde Healthcare to advance respiratory remote patient monitoring | San Francisco (California, US) & Cambridge (Massachusetts, US) – Spire Health, the leading provider of respiratory remote patient monitoring (RPM), today announced the closing of a $38 million equity financing, led by Gilde Healthcare P... |
| 13.07.2021 | LAVA Therapeutics announces treatment of first patient in Phase 1/2a clinical trial | Utrecht (the Netherlands) & Philadelphia (US) – Gilde Healthcare portfolio company LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on developing bispecific gamma-delta T cell engagers (bsTCEs) to transform the tre... |
| 07.07.2021 | Adcendo appoints Michael Pehl as Chief Executive Officer | Utrecht (the Netherlands) & Copenhagen (Denmark) – Gilde Healthcare portfolio company Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appoint... |
| 02.07.2021 | Gilde Healthcare portfolio company Nyxoah realizes successful IPO at NASDAQ | Utrecht (the Netherlands) & Mont-Saint-Guibert (Belgium) – Gilde Healthcare portfolio company Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Ap... |
| 01.07.2021 | Gilde Healthcare portfolio company CVRx realizes successful IPO at Nasdaq | Utrecht (the Netherlands) & Minneapolis (USA) – Gilde Healthcare portfolio company CVRx Inc., a commercial-stage medical device company focused on innovative and minimally invasive neuromodulation solutions for patients with cardiovascu... |
| 07.06.2021 | Nyxoah BETTER SLEEP trial reaches its primary endpoints | Utrecht (the Netherlands) & Mont-Saint-Guibert (Belgium) – Nyxoah, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the BE... |
| 02.06.2021 | Gilde Healthcare appoints Joep Muijrers to lead investments in public markets | Utrecht (the Netherlands) – Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, today announced the appointment of Dr. Joep Muijrers to the investment team of its Venture & Growth capital fund. Joep w... |
| 25.05.2021 | Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital | Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Or... |
| 06.05.2021 | Gilde Healthcare acquires majority stake in Danish drug development consultancy KLIFO to support international growth ambitions | Utrecht (the Netherlands) and Copenhagen (Denmark) – Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a leading Northern European drug development consultancy with significant experience in partnering with biotech and pha... |
| 29.04.2021 | Gilde Healthcare participates in €51M series A financing of Danish biopharmaceutical start-up ADCendo | Utrecht (the Netherlands) and Copenhagen (Denmark) – ADCendo ApS (“Adcendo”), a Danish biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a €51 millio... |
| 27.04.2021 | The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med | Utrecht (the Netherlands) and Freienstau – The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and contract manufacturer of high-quality medical components ... |
| 26.04.2021 | Gilde Healthcare supports national roll out of dental chain Tandarts Today | Utrecht and Eindhoven (the Netherlands) – Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, announces its investment in dental chain Tandarts Today. With this acquisition, Gilde Healthcare enters the Du... |
| 19.04.2021 | RAD-x adds Medizin Center Bonn to its fast growing diagnostic imaging platform | Utrecht (the Netherlands) and Mannheim (Germany) – RAD-x, the leading European diagnostic imaging practice operator and portfolio company of Gilde Healthcare Private Equity, is adding Medizin Center Bonn (MCB) to its group. MCB provides cut... |
| 16.04.2021 | LUMICKS raises $93 million in Series D financing | Amsterdam, the Netherlands – LUMICKS, a leading, next generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D ... |
| 25.03.2021 | Gilde Healthcare announces successful pricing of Nasdaq IPO of portfolio company, Lava Therapeutics | Utrecht, the Netherlands – Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, today announced that its portfolio company, LAVA Therapeutics (Nasdaq: LVTX), has successfully achieved pricing of its Nasdaq... |
| 17.03.2021 | Amphista Therapeutics raises $53M in Series B round co-led by Gilde Healthcare to advance next generation targeted protein degradation assets | Glasgow, UK - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round from an investor syndicate co-led by Gilde H... |
| 01.03.2021 | Ace Pharmaceuticals strengthens shareholders base | Zeewolde, the Netherlands – Ace Pharmaceuticals (Ace), a specialized pharmaceutical company in medical need medicines, strengthens its shareholders base with the addition of Gilde Buy Out Partners and Gilde Healthcare. Founded in 1990 and ... |
| 01.03.2021 | Axonics® expands into stress urinary incontinence with the acquisition of Bulkamid® | IRVINE, California US – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bow... |
| 22.02.2021 | LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic | Utrecht, The Netherlands and Philadelphia, USA – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced ... |
| 19.02.2021 | Acacia Pharma (EURONEXT: ACPH) raises EUR 27 million for US launch | Cambridge, UK and Indianapolis, US – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments... |
| 02.02.2021 | Nyxoah and Vanderbilt University enter exclusive licensing agreement | Utrecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), to... |
| 28.01.2021 | Acacia Pharma launches BYFAVO™ in the United States for procedural sedation in adults undergoing medical procedures lasting 30 minutes or less | Cambridge (UK), Indianapolis (US) and Utrecht (the Netherlands) - Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients und... |
| 26.01.2021 | Nyxoah announces full-body MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) | Utecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), tod... |
| 20.01.2021 | Acacia Pharma wins BEL Company of the Year for the second consecutive year | This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge (United Kingdom) and Utrecht (the Netherlands) – Acacia Pharma Group plc (EURONEXT: ACPH), a commercial ... |
| 19.01.2021 | RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group | Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group. Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and ... |
| 08.01.2021 | AM-Pharma announces enrollment and financing of COVID-19 cohort in phase III REVIVAL trial | Utrecht (the Netherlands) - AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, today announced that the first patients with COVID-19 infection and sepsis-associated acute kidney injury (S... |
| 06.01.2021 | Gilde Healthcare leads $28 million financing in Volta Medical to revolutionize persistent AFib ablation | Marseille (France) - Utrecht (the Netherlands) – Volta Medical, a French-based HealthTech startup, pioneering novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised an 28 m... |
| 01.12.2020 | Gilde Healthcare participates in €51M series A financing of Noema Pharma | Basel (Switzerland) – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announced it has successfully concluded an oversubscribed Series A financing round, raising €51 million (CHF54 mi... |
| 01.12.2020 | Vesper Medical Announces First Enrollment in the VIVID Trial | Malvern, PA — Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced initiation of its U.S. Food and Drug Administration (FDA) Investigational Exemption (IDE) study - Venous stent for the Iliofemoral V... |
| 19.11.2020 | MercachemSyncom changes name to Symeres | Nijmegen (The Netherlands) – MercachemSyncom today announced that it will change its name and operate under the registered trade name of Symeres. The new name reflects the strategic evolution of the company, with the growth of integrated... |
| 16.11.2020 | Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases | Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis Amsterdam, The Netherlands - Calypso Biotech, a company developi... |
| 13.11.2020 | Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry | IRVINE, Calif. — (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today an... |
| 12.11.2020 | AM-PHARMA Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury | Utrecht, The Netherlands – AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, today announced that it has enrolled the first patient in its global Phase III trial named REVIVAL (REcombina... |
| 09.11.2020 | Drug discovery CRO MercachemSyncom adds biology services through acquisition | Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox servic... |
| 16.10.2020 | Eargo, Inc. announces pricing of Initial Public Offering | San Jose (CA, US) – Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock a... |
| 17.09.2020 | Lava Therapeutics announces $83 million series C financing to advance novel gamma-delta T cell engager programs | Utrecht (The Netherlands) and Philadelphia – Gilde Healthcare company Lava Therapeutics announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. The financ... |
| 17.09.2020 | Nyxoah raises up to €85 million (US$100M) in successful initial public offering | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, SOUTH AFRICA, CANADA, JAPAN Utrecht (The Netherlands) – Gilde Healthcare company Nyxoah (the “Co... |
| 27.08.2020 | Nyxoah announces intention to launch an Initial Public Offering on Euronext Brussels | Mont-Saint-Guibert (Belgium) and Utrecht (The Netherlands) – Nyxoah S.A. (“Nyxoah” or the “Company”) a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered... |
| 24.08.2020 | Acacia Pharma commercially launches BARHEMSYS® in the US for the treatment of prevention of postoperative nausea & vomiting | Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatmen... |
| 14.08.2020 | Acacia Pharma raises €25M to launch BARHEMSYS® and BYFAVO™ in the US | Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatmen... |
| 11.08.2020 | Lumeon raises $30M to fuel growth in the US | Boston (Massachusetts, US) and Utrecht (The Netherlands) – Lumeon, the leader in care pathway orchestration, today announced that it has closed $30M in Series D funding led by new investors Optum Ventures and Endeavour Vision, with particip... |
| 31.07.2020 | LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapy via avidity analyses | Utrecht (The Netherlands) and Amsterdam (The Netherlands) – LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development. By quantifying binding strength between immune... |
| 30.07.2020 | Gilde Healthcare Partners co-leads $71 million financing round in hearing aid manufacturer Eargo | Utrecht (The Netherlands) and Boston (Massachusetts, US) – Eargo Inc. (San Jose, CA), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the closing of a $71 million equity fina... |
| 29.07.2020 | Gilde Healthcare leads $60 million growth financing round in healthtech scale-up Withings | Paris (France) and Utrecht (The Netherlands) – Withings, an early pioneer of connected health devices , announced today that it raised a $60 million Series B funding round, co-led by Gilde Healthcare, Idinvest Partners and Bpifrance with ad... |
| 08.07.2020 | CVRx® raises $50 million in new equity financing | Utrecht (The Netherlands) and Boston (Massachusetts, US) – CVRx, Inc., a private medical device company commercialising a novel technology that treats patients suffering from chronic heart failure ("HF") and resistant hypertension... |
| 03.07.2020 | CVRx® announces publication of BeAt-HF clinical study results in the journal of the American College of Cardiology | MINNEAPOLIS (US) – CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”). Results from the tri... |
| 03.07.2020 | Acacia Pharma announces US FDA approval of BYFAVO™ (remimazolam) for procedural sedation | CAMBRIDGE (UK), INDIANAPOLIS (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments ... |
| 18.06.2020 | Gilde Healthcare leads $39 million in Series B financing in Big Health | SAN FRANCISCO, CA (US), UTRECHT (THE NETHERLANDS) – Big Health, the global leader in digital therapeutics dedicated to helping millions back to good mental health, today announced it has raised $39 million in a Series B financing, led by Gi... |
| 27.05.2020 | Inari Medical closes upsized initial public offering | IRVINE, CALIFORNIA – Inari Medical Inc. today announced the closing of its initial public offering on NASDAQ. Inari is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suf... |
| 15.05.2020 | Lava Therapeutics announces collaboration with Johnson & Johnson to develop bi-specific gamma-delta T-cell engager therapeutics | Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Dutch biopharmaceutical start-up Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Ph... |
| 11.05.2020 | Vapotherm raises $87 million via public offering | Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of... |
| 11.05.2020 | Axonics Modulation Technologies raises $130 million via public offering | Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Syst... |
| 31.03.2020 | Gilde Healthcare raises €416 million ($450 million) venture and growth capital fund | Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Gilde Healthcare today announces the first and final close of Gilde Healthcare V, a €416 million ($450 million) venture and growth capital fund. The new fund, which was oversubscri... |
| 24.03.2020 | Respiratory company Vapotherm provides business update in response to COVID-19 pandemic | New Hampshire (United States) – Vapotherm, Inc. (NYSE: VAPO), the Gilde Healthcare company focused on the commercialization of its proprietary Hi-VNI Technology products that are used to treat patients suffering from respiratory distress, t... |
| 03.03.2020 | Acacia Pharma announces year and results and outlook 2020 | Cambridge (United Kingdom) and Indianapolis (United States) – Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergo... |
| 27.02.2020 | Acacia Pharma announces US FDA approval of BARHEMSYS® to treat PONV | Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare company Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on therapeutic solutions improving the care of patients undergoing significant ... |
| 20.02.2020 | Ablative Solutions Announces Publication of Data from the Peregrine Post-Market Study in the Journal of the American College of Cardiology: Cardiovascular Interventions | SAN JOSE, Calif. — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced that positive six-month results from the Peregrine Post-Market Study demonstrating the safety and efficacy o... |
| 13.02.2020 | First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis | First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatment... |
| 04.02.2020 | Axonics® receives reimbursement approval in Germany for its Sacral Neuromodulation | Irvine, CA (United States) – Gilde Healthcare portfolio company Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulatio... |
| 24.01.2020 | Acacia Pharma wins BEL Small Company of the Year Award 2019 | Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare portfolio company Acacia Pharma Group plc (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international ma... |
| 10.01.2020 | Acacia Pharma signs strategic in-licensing and finance agreement with Cosmo Pharmaceuticals N.V. | Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare portfolio company Acacia Pharma (EURONEXT: ACPH), a pharmaceutical company commercialising hospital products for US and international markets, announces it has e... |
| 09.01.2020 | MercachemSyncom acquires the European operations of Alcami | Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, has announced that it has acquired Alcami’s European cGMP CMC drug substance devel... |
| 09.01.2020 | Lava Therapeutics appoints immuno-oncology experts James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. to advisory board | Utrecht (the Netherlands) and Philadelphia (United States) – Gilde Healthcare company Lava Therapeutics (“LAVA”) announced that James P. Allison, Ph.D., a 2018 Nobel Prize recipient in Physiology or Medicine for his discovery of cancer ther... |
| 18.12.2019 | Gilde Healthcare exits occupational health provider BlijWerkt to Mentha Capital | Utrecht (the Netherlands) – Gilde Healthcare today announced it has sold its majority stake in occupational health provider BlijWerkt to Mentha Capital, subject to approval by the Dutch Healthcare Authority. Led by Gilde, BlijWerkt has beco... |
| 04.12.2019 | Lumeon partners with Medtronic on value-based care | Utrecht (the Netherlands) and London, (UK) – Lumeon, the leader in Care Pathway Management (CPM), today announced that it has entered a strategic partnership with Medtronic, a global leader in medical technology, services, and solutions, th... |
| 21.11.2019 | Axonics® raises $110 million via Public Offering of Common Stock | Irvine, CA (US) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatme... |
| 14.11.2019 | Axonics® announces U.S. FDA approval for its sacral neuromodulation system for urinary clinical indications | Irvine, CA (US) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladde... |
| 30.10.2019 | Sanifit announces positive Phase 2b data in cardiovascular calcification | Utrecht (The Netherlands), Palma (Spain) and San Diego (US) – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPS... |
| 28.10.2019 | Nyxoah publishes positive clinical data | Utrecht (The Netherlands) and Mont-Saint-Guibert (Belgium) – Nyxoah S.A., a healthtech company focused on the development of innovative solutions and services for sleep related disorders, announced today the publication of data from the BLA... |
| 03.10.2019 | Axonics® Provides Full One-Year Results from ARTISAN-SNM Pivotal Study at AUGS/IUGA Joint Scientific Meeting | Durable Outcomes Highlighted in Plenary Session Presentation; Expanding on Positive Topline Data Released in August More than 350 Physicians Attended a Symposium Highlighting Hands-on Physician Experience with the Recently FDA-Approved Axo... |
| 26.09.2019 | Acacia Pharma announces new BARHEMSYS® PDUFA date of 26 february 2020 | Utrecht (The Netherlands) and Cambridge (Massachusetts) – Gilde Healthcare company Acacia Pharma (BRU:ACPH), a pharmaceutical company developing and commercializing hospital products for US and international markets, announces that the US F... |
| 09.09.2019 | Axonics receives FDA approval for neurostimulator to treat fecal incontinence | Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare company Axonics, a medical technology company that commercializes a novel implantable rechargeable sacral neuromodulation (“SNM”) device for the treatment of urinary an... |
| 03.09.2019 | Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension | SAN JOSE, Calif. and PARIS – Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced 12-month results from the Peregrine Post-Market Clinical Trial, which were presented today during ... |
| 19.08.2019 | CVRx obtains FDA approval for heart failure neuromodulation device | Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare company CVRx, Inc., announces today that it received Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) to market its BAROSTIM NEO devic... |
| 25.07.2019 | Gilde Healthcare announces acquisition of Breath Therapeutics by Zambon for up to €500 million | Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare today announced it has sold its shareholding in portfolio company Breath Therapeutics to Zambon, an Italian multinational pharmaceutical company. Zambon will pay an ini... |
| 16.07.2019 | AM-Pharma Raises Record Financing of €116m [$133m] for Phase III Trial in Acute Kidney Injury | Bunnik, The Netherlands – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphat... |
| 11.07.2019 | Ablative Solutions Announces Appointment of Kate Rumrill as President and Chief Executive Officer | San Jose, Calif., US - Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced that Kate Rumrill has been appointed as the new President and CEO. Rumrill will also serve on the board o... |
| 08.07.2019 | Acacia Pharma plans to resubmit the BARHEMSYS® NDA in Q3 2019 | Cambridge, UK and Indianapolis, US - Acacia Pharma, a pharmaceutical company developing and commercialising hospital products for US and international markets, announces receipt of the official Type A meeting minutes from the US Food and Dr... |
| 02.07.2019 | Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | IRVINE, Calif., /PRNewswire/ -- Inari Medical, Inc. announced today that the company has appointed Thomas M. Tu, M.D. as Chief Medical Officer. Dr. Tu is a pioneer in definitive catheter-based treatment of pulmonary embolism (PE). He was t... |
| 26.06.2019 | Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise | Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private... |
| 04.06.2019 | Gilde Healthcare co-leads $37M financing of Vesper Medical to complete development of its Duo Venous Stent System | Utrecht (The Netherlands), Cambridge (United States) - Gilde Healthcare today announces its investment in Vesper Medical, Inc. (Wayne, PA), a developer of medical devices for minimally invasive peripheral vascular procedures. Gilde Healthca... |
| 20.05.2019 | QIAstat-Dx gains 510(k) clearance by FDA, triggering milestone payment for Gilde Healthcare | Utrecht, The Netherlands - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced 510(k) clearance of its QIAstat-Dx syndromic testing system by the U.S. Food and Drug Administration. The regulatory approval will trigger a ... |
| 26.03.2019 | Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome Contacts: | Munich, Germany and Menlo Park, Calif. — Breath Therapeutics, a private company developing advanced inhaled therapeutics in severe pulmonary orphan diseases, announced today the initiation of the Phase 3 BOSTON clinical studies of L CsA i f... |
| 19.03.2019 | Nyxoah receives European CE Mark approval for the Genio™ system to treat sleep apnea | Utrecht, The Netherlands and Mont-Saint-Guibert, Belgium – Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark... |
| 11.03.2019 | Gilde Healthcare acquires healthcare food supplier Eetgemak from Value8 | Utrecht and Frankfurt - Gilde Healthcare, the European specialist investor in healthcare, acquires a majority stake in Eetgemak from stock listed investment firm Value8. The acquisition is the first investment in Gilde Healthcare’s new €200... |
| 07.03.2019 | Gilde Healthcare raises €200 million for new private equity fund | Utrecht (the Netherlands) and Frankfurt (Germany) – Gilde Healthcare, the European specialist investor in healthcare, today announces that it has raised €200 million for its third private equity fund, Gilde Healthcare Services III. The fund... |
| 05.03.2019 | Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update | IRVINE, CA – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bow... |
| 21.02.2019 | Gilde Healthcare leads EUR 20M Series A financing round of Calypso Biotech | Utrecht, The Netherlands and Boston, US - Calypso Biotech (Amsterdam, The Netherlands), an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing led by... |
| 14.02.2019 | Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System | Irvine, CA – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bow... |
| 22.01.2019 | Acacia Pharma reports positive cardiac safety data for BARHEMSYS™ | Cambridge, UK and Indianapolis, US - Acacia Pharma (EURONEXT: ACPH) announces results from its latest study of BARHEMSYS™, its anti-emetic currently under FDA review for the management of post-operative nausea & vomiting (PONV). The st... |
| 03.01.2019 | Gilde Healthcare leads USD 77 million financing round of hypertension company Ablative Solutions | Utrecht (The Netherlands), Boston (United States) – Ablative Solutions, Inc. (Kalamazoo, Michigan), a medtech company pioneering new approaches for the treatment of hypertension, today announced the first close of its USD 77 million Series ... |
| 12.12.2018 | Acacia Pharma announces positive clinical results for APD403 in chemotherapy induced nausea & vomiting published in Supportive Care in Cancer | Cambridge, UK and Indianapolis, US - Acacia Pharma Group plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH) announces that data and analyses from its positive Phase 2 clinical trial of APD403 (intravenous and oral ami... |
Show more
Mentions in press and media 105
| Date | Title | Description |
| 07.04.2026 | Endovascular Engineering Raises $80M Series C Funding | Endovascular Engineering, Inc., a Menlo Park, CA-based commercial-stage medical technology company, raised $80M in Series C funding. The round was led by Gilde Healthcare and Norwest, with participation from existing investors including San... |
| 21.02.2026 | Digital Mental Health Pioneer Secures $23.7M to Transform Care Access | Big Health raised $23.7 million. This funding will scale its FDA-cleared digital mental health treatments. SleepioRx targets insomnia. DaylightRx addresses generalized anxiety. A recent Centers for Medicare & Medicaid Services policy ch... |
| 15.02.2026 | Big Health Secures $23.7 Million To Scale FDA-Cleared Treatments | Big Health announced it has secured $23.7 million in new strategic funding to accelerate the adoption of its FDA-cleared digital mental health treatments, as health systems increasingly integrate reimbursable digital care into routine pract... |
| 12.02.2026 | Big Health Raises $23.7M in New Funding | Big Health, a San Francisco, CA-based developer of digital treatments for mental health conditions, raised $23.7M in new funding. The round was led by .406 Ventures and AlleyCorp, with participation from CVS Health Ventures, Blue Venture Fu... |
| 18.09.2025 | Capital meets care: 10 venture capital firms transforming healthcare across Europe | Venture capital remains one of the cornerstones of Europe’s innovation landscape, fuelling the growth of startups across every sector. In our last list, we spotlighted 15 VC firms focused on sustainability, underlining how investors are sha... |
| 16.09.2025 | CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development | Experienced executives, Clinton Musil, Sujata Rao, MD, Heike Krupka, PhD, and Andrea Goddard join CatalYm to broaden and accelerate clinical programs into late-stage development Munich, Germany and San Francisco, USA, September 15, 2025 – C... |
| 02.09.2025 | ProVerum: $80 Million Series B Raised For Advancing BPH Treatments | ProVerum Limited is a company that has made significant strides with its development of the ProVee System, a minimally invasive solution specifically designed for treating benign prostatic hyperplasia (BPH). Recently, the company announced ... |
| 26.08.2025 | Irish MedTech startup ProVerum raises €68.6 million to advance new treatment for urological conditions | ProVerum, a MedTech startup based in Dublin, has secured €68.6 million in Series B equity financing to advance the commercialisation of its minimally invasive solution for benign prostatic hyperplasia (BPH). The round was led by MVM Partner... |
| 25.08.2025 | ProVerum: $80 Million Series B Raised For Treating BPH | ProVerum Limited, a leading innovator in urological medical devices, has announced the successful completion of an $80 million Series B equity financing round. This significant capital raise is a major milestone for the company as it moves ... |
| 16.07.2025 | Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment | Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery researc... |
| 15.07.2025 | GT Medical Technologies Raises Additional $16M; Closes $53M Series D Equity Financing | GT Medical Technologies, Inc., a Tempe, AZ-based medical device company raised additional $16M in Series D funding. Backers included FemHealth Ventures and Warren Point Capital. The company intends to use the funds to drive the expansion of... |
| 19.06.2025 | SpliceBio: $135 Million Series B Raised For Expanding Pipeline Of Genetic Medicines | SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the closing of a $135 million Series B financing co-led by new investors EQT Life Sciences a... |
| 11.06.2025 | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio Wed, Jun 11, 2025 09:30 CET Report this content Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as... |
| 06.06.2025 | SpyGlass Pharma Secures $75 Million to Revolutionize Glaucoma Treatment | SpyGlass Pharma, a rising star in the ophthalmic biotechnology sector, has successfully closed a $75 million Series D funding round. This financial boost is a significant leap forward for the company, which is based in Aliso Viejo, Californ... |
| 05.06.2025 | SpyGlass Pharma: $75 Million Series D Raised For Advancing Drug Delivery Platform For Glaucoma Patients | SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. Sands Capital led the Series D funding round, which was joined by Gilde Healthcare and existing investors N... |
| 17.03.2025 | MicroTransponder Secures $65 Million to Revolutionize Stroke Recovery | In the heart of Austin, Texas, a medical device company is making waves. MicroTransponder has just raised $65 million in Series F funding. This investment is a significant step forward in the company’s mission to transform stroke recovery. ... |
| 16.03.2025 | MicroTransponder: $65 Million (Series F) Raised For Enhancing Vivistim Adoption For Chronic Stroke Recovery | MicroTransponder – which is one of the fastest-growing stroke companies – announced it is transforming the stroke continuum of care with its FDA-approved Vivistim Paired VNS System. The company also announced it has raised $75 million led b... |
| 13.03.2025 | MicroTransponder Raises $65M in Series F Funding | MicroTransponder, an Austin, TX-based medical device company, raised $65M in Series F funding. The round was led by US Venture Partners (USVP) and the syndicate of current investors, Osage University Partners, Action Potential Venture Capit... |
| 24.01.2025 | GT Medical Technologies: Pioneering a New Era in Brain Tumor Treatment with $37 Million Series D Funding | In the ever-evolving landscape of medical technology, GT Medical Technologies stands out like a lighthouse in a storm. This Tempe, Arizona-based company has recently secured $37 million in Series D funding, a financial boost that promises t... |
| 22.01.2025 | GT Medical Technologies: $37 Million (Series D) Raised For Improving Lives Of Patients With Brain Tumors | GT Medical Technologies – a medical device company that aims to improve patients’ lives with brain tumors – announced that the company has completed the $37 million first close of a Series D funding round. The funding was led by Evidity Hea... |
| 21.01.2025 | Alleviant Medical: $90 Million Raised For Developing No-Implant Atrial Shunt For Heart Failure | Alleviant Medical – a privately held medical device company developing a no-implant atrial shunt for heart failure – announced a $90 million financing to fund its second pivotal trial. The round was led by Gilde Healthcare, and it also incl... |
| 09.01.2025 | FIRE1: $120 Million Funding Raised For Transforming Heart Failure Care | FIRE1 – a leading connected medical device solutions company – announced the completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. The fundin... |
| 08.01.2025 | FIRE1 Secures $120M for Heart Failure Management Platform | What You Should Know: – FIRE1, a connected medical device company, announced it has secured $120M in funding to advance its mission to transform the lives of millions of people living with heart failure. The round was led by Polaris Partner... |
| 07.01.2025 | FIRE1 heats up with $120M for its heart failure monitor implant | Things are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden signs of heart failure. The Dublin-based company also announced that the FDA has handed down a breakthrough designatio... |
| 07.01.2025 | FIRE1 Secures $120M Financing | FIRE1, a Dublin, Ireland-based connected medical device solutions company, raised $120M in funding. The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and exi... |
| 11.12.2024 | Noema Pharma extends Series B funding to CHF 130 million | EQT Life Sciences’ LSP 7 fund has invested in Noema Pharma. The clinical-stage biotech company headquartered in Basel is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series... |
| 11.12.2024 | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million Wed, Dec 11, 2024 09:30 CET Report this content Proceeds will be used to enable key late-stage clinical trial readouts for asset... |
| 19.08.2024 | Revolutionizing Healthcare: Moximed and PayZen Lead the Charge | In the evolving landscape of healthcare, two companies are emerging as beacons of innovation: Moximed and PayZen. Both are tackling significant challenges in the medical field, albeit from different angles. Moximed is addressing the physica... |
| 17.08.2024 | Moximed: $91 Million (Series D) Closed To Improve Knee Osteoarthritis Care | Moximed, an innovative medical device company with a goal of improving the standard of care for people with knee osteoarthritis (OA), announced the closing on $61 million of Series D preferred stock financing with an option to close on up t... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| 03.05.2024 | Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding Boost | Karius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI... |
| 02.05.2024 | Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test | What You Should Know: – Karius®, a leader in genomic diagnostics for infectious disease, announced today the closing of a $100 million Series C funding round. – Co-led by Khosla Ventures and newcomers 5AM Ventures and Gilde Healthcare, the ... |
| 02.05.2024 | Karius Raises $100M in Series C Funding | Karius, Inc., a Redwood City, CA-based leader in genomic diagnostics for infectious disease, raised $100m in Series C funding. The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was n... |
| 04.03.2024 | Argá Medtech secures €54 million in oversubscribed series B | Argá Medtech’s CSE ablation system enables electrophysiologists to treat any region in the heart safely and efficiently using a single, multi-configurable catheter while titrating lesion depths according to the location within the heart. T... |
| 03.01.2024 | Gilde Healthcare acquires majority stake in Swiss Dental Solutions | |
| 16.11.2023 | 'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair | When it comes to bringing together pharma and financiers, the U.S. leads the way with industrial-scale events like J.P. Morgan in San Francisco and BIO in San Diego. But for the chairman of European life sciences VC firm Sofinnova Partners,... |
| 15.11.2023 | Gilde Healthcare Closes Gilde Healthcare Venture&Growth VI Fund, at €740M | Gilde Healthcare, a Utrecht, The Netherlands-based healthcare investor, closed its Gilde Healthcare Venture&Growth VI fund, at €740m. Fund VI is backed by international investors, including healthcare corporates, (Dutch) pension funds, ... |
| 26.06.2023 | Dutch-based Tagworks Pharmaceuticals raises €59.5M to design effective, safe systemic therapies | The Netherlands-based Tagworks Pharmaceuticals, a company that claims to be a pioneer of Click-to-Release chemistry to deliver effective and safer systemic therapies, announced on Thursday, June 22, that it has raised $65M (approximately €5... |
| 24.04.2023 | Digital health news, funding round up in the prior week; April 24, 2023 | Noah Medical raised $150M; Gilde Healthcare closed a €600M fund; Merck bought Prometheus Biosciences Top Health News Moderna announced a partnership with IBM on Thursday, in which the company will "explore next generation technologies,... |
| 19.04.2023 | Utrecht-based Gilde Healthcare launches new fund at €600M; focuses on Europe and North America | Utrecht-based Gilde Healthcare, a specialised healthcare investor, announced on Wednesday that it has launched a new investment fund called Gilde Healthcare Venture&Growth VI. The new fund has received €600M in commitments and is focuse... |
| 19.04.2023 | Gilde Healthcare Closes €600M Fund | Utrecht, Netherlands-based Gilde Healthcare raised a new investment fund with €600m in commitments. Gilde Healthcare Venture&Growth VI is backed by a balanced mix of international investors, including corporates, banks, pension funds, i... |
| 04.04.2023 | Ysios Capital’s portfolio company Adcendo announces extension of Series A financing to 82M€ to ensure broad development of first-in-class ADC pipeline | 04/04/2023 Nota de prensa YSIOS CAPITAL’S PORTFOLIO COMPANY ADCENDO ANNOUNCES EXTENSION OF SERIES A FINANCING TO 82M€ TO ENSURE BROAD DEVELOPMENT OF FIRST-IN-CLASS ADC PIPELINE Adcendo ApS (“Adcendo”), a biotech company focused on the de... |
| 07.03.2023 | Noema Pharma raises CHF103 million | |
| 05.01.2023 | France's Volta Medical raises €36 million series B to help surgeons treat cardiac arrhythmias and fund more clinical testing | Volta Medical is announcing a €36 million series B fundraise to lift its total investment to above €70 million. Leading the round on this occasion is the US investor Vensana Capital, with participation from Lightstone Ventures and the healt... |
| 17.03.2022 | Gilde Healthcare Closes Gilde Healthcare Private Equity IV, At €517M | Gilde Healthcare, an Utrecht, The Netherlands-based healthcare focused private equity firm, closed Gilde Healthcare Private Equity IV, at €517m. The fund, which received the support from institutional investors from the Netherlands, Germany... |
| 02.02.2022 | French digital health startup Withings works out in Germany with fitness app acquisition | Issy-les-Moulineaux-based health wearables startup Withings has acquired Germany’s personalised workout and nutrition app 8fit. The acquisition of 8fit will allow Withings to further expand its global user footprint, develop cross-sell syne... |
| 20.09.2021 | Clinical progression and €8M funding for Calypso Biotech | Calypso Biotech’s lead program, CALY-002, is a best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 controls immune pathways critically involved in disease onset and maintenance, as well as tissue d... |
| 14.07.2021 | Spire Health closes $38 million financing round led by Gilde Healthcare to advance respiratory remote patient monitoring | San Francisco (California, US) & Cambridge (Massachusetts, US) – Spire Health, the leading provider of respiratory remote patient monitoring (RPM), today announced the closing of a $38 million equity financing, led by Gilde Healthcare P... |
| 29.04.2021 | Gilde Healthcare participates in €51M series A financing of Danish biopharmaceutical start-up ADCendo | Utrecht (the Netherlands) and Copenhagen (Denmark) – ADCendo ApS (“Adcendo”), a Danish biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a €51 millio... |
| 29.04.2021 | Ysios Capital leads a €51M round in Adcendo, also followed up by Novo Seeds, RA Capital Management, HealthCap and Gilde | ADCENDO RAISES €51 MILLION IN SERIES A FINANCING TO ADVANCE NOVEL ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF CANCERS. Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company Plans to build a pipeline o... |
| 17.03.2021 | Amphista Therapeutics raises $53M in Series B round co-led by Gilde Healthcare to advance next generation targeted protein degradation assets | Glasgow, UK - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round from an investor syndicate co-led by Gilde H... |
| 06.01.2021 | Gilde Healthcare leads $28 million financing in Volta Medical to revolutionize persistent AFib ablation | Marseille (France) - Utrecht (the Netherlands) – Volta Medical, a French-based HealthTech startup, pioneering novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised an 28 m... |
| 01.12.2020 | Noema Pharma raises CHF 54 million in Series A financing round | In 2019, Noema Pharma obtained a seed investment from Sofinnova Partners, a leading European life sciences, venture capital firm based in Paris, London and Milan to embark on a new journey to address orphan neurological disorders characteri... |
| 01.12.2020 | Gilde Healthcare participates in €51M series A financing of Noema Pharma | Basel (Switzerland) – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announced it has successfully concluded an oversubscribed Series A financing round, raising €51 million (CHF54 mi... |
| 01.12.2020 | Noema Pharma raises CHF 54 million in Series A financing round | |
| 06.08.2020 | Withings Secures $60 Million to Bridge the Gap Between Consumers and Physicians | The coronavirus pandemic has changed how many industries operate and conduct business. The industry change can readily be seen in the health and medical sectors. Before COVID-19, telemedicine and remote patient monitoring were a rarity, but... |
| 30.07.2020 | Gilde Healthcare Partners co-leads $71 million financing round in hearing aid manufacturer Eargo | Utrecht (The Netherlands) and Boston (Massachusetts, US) – Eargo Inc. (San Jose, CA), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the closing of a $71 million equity fina... |
| 29.07.2020 | Gilde Healthcare leads $60 million growth financing round in healthtech scale-up Withings | Paris (France) and Utrecht (The Netherlands) – Withings, an early pioneer of connected health devices , announced today that it raised a $60 million Series B funding round, co-led by Gilde Healthcare, Idinvest Partners and Bpifrance with ad... |
| 18.06.2020 | Gilde Healthcare leads $39 million in Series B financing in Big Health | SAN FRANCISCO, CA (US), UTRECHT (THE NETHERLANDS) – Big Health, the global leader in digital therapeutics dedicated to helping millions back to good mental health, today announced it has raised $39 million in a Series B financing, led by Gi... |
| 01.04.2020 | Gilde Healthcare Raises €416M Venture And Growth Capital Fund | Utrecht, the Netherlands, and Cambridge, Massachusetts-based Gilde Healthcare closed Gilde Healthcare V, a €416m ($450m) venture and growth capital fund. Gilde Healthcare V is backed by a balanced mix of international investors including ba... |
| 31.03.2020 | Gilde Healthcare raises €416 million ($450 million) venture and growth capital fund | Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Gilde Healthcare today announces the first and final close of Gilde Healthcare V, a €416 million ($450 million) venture and growth capital fund. The new fund, which was oversubscri... |
| 25.07.2019 | Gilde Healthcare announces acquisition of Breath Therapeutics by Zambon for up to €500 million | Utrecht (The Netherlands), Cambridge (United States) – Gilde Healthcare today announced it has sold its shareholding in portfolio company Breath Therapeutics to Zambon, an Italian multinational pharmaceutical company. Zambon will pay an ini... |
| 04.06.2019 | Gilde Healthcare co-leads $37M financing of Vesper Medical to complete development of its Duo Venous Stent System | Utrecht (The Netherlands), Cambridge (United States) - Gilde Healthcare today announces its investment in Vesper Medical, Inc. (Wayne, PA), a developer of medical devices for minimally invasive peripheral vascular procedures. Gilde Healthca... |
| 07.03.2019 | Gilde raises €200M European healthcare investment fund W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Gilde Healthcare has raised €200 million ($226 million) to invest in suppliers of medical products and other health businesses. The fund moves the amount raised by Gilde’s healthcare investment vehicles past the €1 billion mark. Sponsored b... |
| 07.03.2019 | Gilde Healthcare raises €200 million for new private equity fund | Utrecht (the Netherlands) and Frankfurt (Germany) – Gilde Healthcare, the European specialist investor in healthcare, today announces that it has raised €200 million for its third private equity fund, Gilde Healthcare Services III. The fund... |
| 07.03.2019 | Gilde raises €200M European healthcare investment fund | Gilde Healthcare has raised €200 million ($226 million) to invest in suppliers of medical products and other health businesses. The fund moves the amount raised by Gilde’s healthcare investment vehicles past the €1 billion mark. European he... |
| 26.02.2019 | String of successes for Merck Serono spin-offs | |
| 21.02.2019 | Gilde Healthcare leads EUR 20M Series A financing round of Calypso Biotech | Utrecht, The Netherlands and Boston, US - Calypso Biotech (Amsterdam, The Netherlands), an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing led by... |
| 03.01.2019 | Gilde Healthcare leads USD 77 million financing round of hypertension company Ablative Solutions | Utrecht (The Netherlands), Boston (United States) – Ablative Solutions, Inc. (Kalamazoo, Michigan), a medtech company pioneering new approaches for the treatment of hypertension, today announced the first close of its USD 77 million Series ... |
| 23.05.2018 | Gilde Healthcare leads EUR 16M financing round of Dutch immuno-oncology startup LAVA | 's-Hertogenbosch, The Netherlands - Lava Therapeutics ("LAVA") today announced it has raised EUR 16 million in its first major institutional financing round from an investor syndicate led by Gilde Healthcare. The funding will supp... |
| 03.04.2018 | Gilde Healthcare leads USD 27 million financing round of innovative catheter company Inari Medical | Irvine, US - Inari Medical, Inc., announced the close of a Series C financing totaling $27.0 million. The financing was led by new investor Gilde Healthcare and was joined by Versant Ventures and U.S. Venture Partners. Geoff Pardo of Gilde ... |
| 05.03.2018 | Gilde Healthcare company Acacia Pharma successfully raises EUR 40 Million via an Initial Global Offering on Euronext Brussels | Utrecht, The Netherlands - Acacia Pharma Group plc announces its Initial Global Offering and listing on Euronext Brussels. Shares in the Initial Global Offering are issued to institutional investors in Europe, the UK and the US, raising gro... |
| 30.01.2018 | Gilde Healthcare leads EUR 40 Million financing in Irish healthtech company FIRE1 | Dublin, Ireland – Foundry Innovation & Research 1, Ltd. ("FIRE1"), today announced the close of a Series C financing totaling EUR 40 Million ($48.5 Million). The financing was led by Gilde Healthcare with the participation of ... |
| 06.07.2017 | Gilde Healthcare participates in EUR 31 million financing round of neuromodulation company Axonics | Utrecht, the Netherlands — Gilde Healthcare today announces its investment in Axonics (Paris, France and Irvine, US), developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunct... |
| 08.03.2017 | Gilde Healthcare participates in EUR 43.5 million financing round of German respiratory disease company Breath Therapeutics | Utrecht, the Netherlands — Gilde Healthcare today announces its investment in Breath Therapeutics, a company developing advanced drug-aerosol therapeutics in pulmonary orphan indications. Gilde Healthcare participated in a €43.5 million Ser... |
| 07.07.2016 | Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah | Mont-Saint-Guibert, Belgium – Nyxoah S.A., a medical device company focused on developing a neurostimulation based, disruptive therapy for patients suffering from Obstructive Sleep Apnea (OSA), announced today it has raised €18 million ($20... |
| 14.06.2016 | Gilde Healthcare Closes Fourth Venture Capital Fund, at €250M | Gilde Healthcare, an Utrecht, The Netherlands and Cambridge, Massachusetts-based venture capital firm, closed its fourth fund, at €250m ($285m). Gilde Healthcare IV is backed by a mix of international investors including cornerstone investo... |
| 14.06.2016 | Gilde Healthcare closes oversubscribed €250 million ($285 million) later stage and growth capital fund | Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million ($285 million) later stage and growth capital fund. Th... |
| 14.06.2016 | Gilde Healthcare Raises $285M for Fourth Fund | Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million ($285 million) later stage and growth capital fund. The new fund, which was oversubscribed, is targeting inves... |
| 11.04.2016 | STAT Diagnostica cierra una ronda de €25M, acuden GildeHC, Kurma, Boehringer, Ysios Capital, CaixaCR, Axis e Idinvest Partners | 11/04/2016 STAT DIAGNOSTICA CIERRA UNA RONDA DE €25M, ACUDEN GILDE HEALTHCARE, KURMA PARTNERS, BOEHRINGER INGELHEIM, YSIOS CAPITAL, CAIXA CAPITAL RISC, AXIS E IDINVEST PARTNERS. STAT Diagnostica, compañía especializada en el desarrollo de... |
| 11.04.2016 | Daily funding roundup - April 11, 2016 | Ticket Monster raised $40M; STAT-Diagnostica closed Series C; Marxent received $10M investment Habito, a London-based online mortgage broker, raised £1.5 million (approximately $2.13 million) in seed funding in a round led by Mosaic Venture... |
| 11.04.2016 | Gilde Healthcare leads EUR 25 million financing round of Medical Diagnostics company STAT-Diagnostica | BARCELONA, Spain – Medical diagnostics company STAT-Diagnostica has closed a Series C financing round totaling EUR 25 million. The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system. Gi... |
| 08.09.2015 | Sanifit cierra una ronda de €36,6M liderada por Ysios. Acuden Caixa CR, Lundbeck fonden, Forbion, Gilde, Edmond Rothschild y Baxter | 08/09/2015 SANIFIT CIERRA UNA RONDA DE €36,6 MILLONES LIDERADA POR YSIOS. ACUDEN CAIXA CAPITAL RISC, Y LOS INTERNACIONALES LUNDBECK FONDEN, FORBION, GILDE, EDMON DE ROTHSCHILD Y BAXTER. La empresa biofarmacéutica Laboratoris Sanifit S.L.,... |
| 08.09.2015 | Gilde Healthcare participates in EUR 36.6M financing round of cardiovascular company Sanifit | Utrecht, The Netherlands and Palma de Mallorca, Spain – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, today announces that it has raised €36.6M in a late stage Series C financing round. The company is focused on the ... |
| 21.06.2015 | Main Capital II realizes successful exit of Zetacom Business Communications | With pleasure we announce the complete sale of the majority stake in Zetacom Group to Gilde Healthcare. Zetacom is a value added system integrator for telecommunication solutions in the enterprise market. Zetacom delivers innovative communi... |
| 09.06.2015 | Gilde Healthcare leads £6 million ($9.4 million) financing round of Digital Health company Qinec | London – Qinec, a pioneer in Personalized Healthcare Management, today announced that it has secured £6 million in Series B funding, led by Gilde Healthcare. Existing investors Amadeus Capital Partners and Archimedia participated as well. ... |
| 21.01.2015 | Gilde Healthcare raises a €100 million lower mid-market healthcare services fund | Utrecht, The Netherlands – Gilde Healthcare, the private equity firm dedicated to the healthcare sector, today announces the first and final close of its €100 million Healthcare Services fund, Gilde Healthcare Services II. The new fund will... |
| 19.09.2014 | Gilde Healthcare Portfolio Company ProQR raises $97.5M in bumped up IPO | Utrecht, the Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces that its portfolio company ProQR Therapeutics priced its initial public offering... |
| 12.09.2014 | AM-Pharma Closes €12.2M Financing | AM-Pharma B.V., a Bunnik, The Netherlands-based biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, closed a €12.2m financing. The round was led by Gilde Healt... |
| 23.06.2014 | Gilde Healthcare company Definiens closes €15M financing round to expand into digital tissue diagnos | Definiens AG, a Munich, Germany-based provider of a tissue diagnostics platform aimed at helping physicians improve treatment announced that it has closed a round of financing for € 15 Million. The round was co-led by new investor Wellingto... |
| 07.04.2014 | Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm | EXETER, New Hampshire - Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3... |
| 09.01.2014 | Viroclinics Biosciences Receives Majority Investment from Gilde Healthcare Services | Viroclinics Biosciences, a Rotterdam, the Netherlands-based virology contract research organization, received a majority investment from Gilde Healthcare Services. The amount of the deal was not disclosed. Founded in 2001 as a spin-off from... |
| 30.11.2013 | Gilde Healthcare Closes €145M Growth Capital Fund | Utrecht, The Netherlands and Cambridge, MA, USA-based investment firm Gilde Healthcare held the final close of its €145m ($200m) transatlantic growth capital fund. Gilde Healthcare III (GHC III) is backed by a mix of international corporate... |
| 26.11.2013 | Gilde Healthcare closes €145 million ($200 million) transatlantic growth capital fund | Utrecht (The Netherlands) and Cambridge (USA, MA) – Gilde Healthcare, the specialist investment firm, today announces the final close of its €145 million ($200 million) transatlantic growth capital fund, Gilde Healthcare III (GHC III). The ... |
| 01.10.2012 | Gilde Healthcare III leads EUR 10 million private financing of Definiens AG | Munich, Germany – Definiens AG, the leader in Image Analysis for Digital Pathology, today announced that it has closed a private round of financing of €10 million. The financing was led by Gilde Healthcare Partners. Existing investors inclu... |
| 01.10.2012 | Definiens Secures 10M EUROS | MUNICH, GERMANY, Leader in Image Analysis for Digital Pathology, today announced that it has closed a private round of financing of EURO10 million. The financing was led by new investor Gilde Healthcare Partners. >> Click here for ... |
| 14.09.2012 | Gilde Healthcare Partners Leads USD 17 million Private Financing Round of iWalk, Inc. | BEDFORD, Mass – iWalk Inc., the leader in Personal Bionics, announced that it has closed a private equity financing round of $17 million led by Gilde Healthcare Partners. Existing investors, including WFD Ventures, General Catalyst Partners... |
| 13.09.2012 | iWalk Gets Moving $17M in Series D | BEDFORD, MA, Leader in Personal Bionics, today announced that it has closed a private Series D equity financing round of $17 million >> Click here for more funding data on iWalk >> To export iWalk funding data to PDF and Exc... |
| 13.09.2012 | iWalk Closes $17M Series D Equity Financing | iWalk Inc., a Bedford, Mass.-based developer of Personal Bionics products, has closed a $17m Series D equity financing round. The financing was led by new investor Gilde Healthcare Partners, with participation from existing investors WFD Ve... |
Show more